Novartis Confident About Transforming CSU Landscape
And Has High Hopes For CAR-T In Immunology
With its BTK inhibitor remibrutinib advancing through Phase III trials and work getting started on a CAR-T therapy for lupus, Novartis’s Marie-France Tschudin tells Scrip that the Swiss major’s immunology pipeline is in a healthy state.
